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Abstract
Background In Ghana, there are issues with the diagnosis of typhoid fever; these include delays in diagnosis, concerns about 
the accuracy of current tests, and lack of availability. These issues highlight the need for the development of a rapid, accurate, 
and easily accessible diagnostic test. The aim of this study was to conduct an early economic analysis of a hypothetical rapid 
test for typhoid fever diagnosis in Ghana and identify the necessary characteristics of the test for it to be cost effective in Ghana.
Methods An early cost-utility analysis was conducted using a decision tree parameterized with secondary data sources, with 
reasonable assumptions made for unknown parameters. The patient population considered is individuals presenting with symp-
toms suggestive of typhoid fever at a healthcare facility in Ghana; a time horizon of 180 days and the Ghanaian national health 
service perspective were adopted for the analysis. Extensive sensitivity analysis was undertaken, including headroom analysis.
Results The results here show that for a hypothetical test to perform better than the existing test (Widal) in terms of QALYs 
gained and cost effectiveness, it is necessary for it to have a high specificity (at least 70%) and should not be priced more 
than US$4. The overall value of conducting research to reduce uncertainty (over 5 years) is US$3287.
Conclusion The analysis shows the potential for the hypothetical test to replace the Widal test and the market potential of 
developing a new test in the Ghanaian setting.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4166 9-019-0159-7) contains 
supplementary material, which is available to authorized users.
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Key Points for Decision Makers 
This study has wider implications for the early economic 
evaluation of diagnostic tests by contributing to a limited 
evidence base and identifying areas requiring further 
research.
A high specificity (at least 70%) is a key test character-
istic requirement for the hypothetical test (HT-test) to be 
able to improve current practice, and the HT-test is likely 
to improve current practice when used to replace the cur-
rent test rather than as triage or add-on.
1 Introduction
Typhoid fever is an acute infection caused by the bac-
teria Salmonella typhi and paratyphi [1]. Transmission 
occurs via the consumption of food or water contaminated 
with the pathogens rather than person-to-person [2], and 
humans serve as the only natural host and reservoir for the 
causative organisms [3]. Typhoid fever remains an impor-
tant cause of disease worldwide [4], but particularly, in 
resource-limited countries [5]. This is as a result of poor 
hygiene practices [6] and an inadequate diagnostic labo-
ratory capacity to differentiate typhoid fever from other 
febrile conditions [7].
In Ghana (a resource-limited country), reported annual 
incidence of typhoid fever in 2017 was 60,892 cases [8]. 
Typhoid fever ranks among the 20 leading causes of out-
patient illness in the country, accounting for 0.92% of all 
hospital admissions [9]. The two tests for typhoid fever 
diagnosis in Ghana are the Widal test and blood culture 
[10]. Compared with blood culture, the Widal test is eas-
ier and requires fewer resources to perform; however, the 
Widal test is an inaccurate indicator of typhoid fever [11, 
12], resulting in inappropriate treatment frequently being 
 S. N. Frempong et al.
administered [10]. The treatment of individuals falsely 
testing positive for typhoid has led to the development 
of resistance of Salmonella typhi and paratyphi to treat-
ments such as chloramphenicol, and this has resulted in 
an increase in the use of the more expensive ciprofloxacin 
in Ghana [10]. The alternative to the Widal test, blood 
culture, lacks sensitivity [7], meaning that the disease will 
be missed in many patients, resulting in lost opportunities 
for treatment, which might lead to increased morbidity and 
mortality. Furthermore, culture requires equipment, sup-
plies, trained laboratory personnel, and electricity, which 
may not be available in primary healthcare facilities in 
Ghana, and when performed, can take 2–3 days before test 
results are obtained. Thus, diagnosis may be delayed and 
patients may end up with complications such as intestinal 
perforation resulting in death if treatment is postponed 
or patients are lost to follow up [13]. Furthermore, those 
without typhoid fever may receive unnecessary and inap-
propriate antimicrobial treatment if treated presumptively 
whilst awaiting results [5]. Another issue is that typhoid 
fever most closely clinically resembles other febrile con-
ditions such as malaria and is easily misdiagnosed with-
out laboratory confirmation [14], which could lead to an 
overprescribing of antimalarial therapies associated with 
a huge economic impact on the Ghanaian economy [15]. 
Therefore, the development of a test for typhoid fever 
in Ghana that is accurate, simple, and affordable with a 
quick turnaround time for typhoid fever has an obvious 
attraction.
The aim of this study was to conduct an early economic 
evaluation to examine the potential cost effectiveness of a 
hypothetical test (hereafter referred to as the HT-test) in 
Ghana, with specific focus on the estimation of the maxi-
mum price and the minimum test performance required 
for the HT-test to be cost effective in comparison with 
the Widal test. In a context of ever-increasing demand to 
demonstrate value for money, technology developers can 
no longer assume that products developed will be adopted 
and funded. Thus, research and development of new tech-
nologies should be driven by considerations of value to 
payers of healthcare, and early economic evaluation has 
much conceptual attractiveness in this regard. Early eco-
nomic evaluation is a tool that is useful for technology 
developers to help them understand the value of a new 
technology to payers, the expected commercial viability, 
the risks, and the potential return on investment in the 
technology. The value of such analyses is that they can be 
cost saving by directing future research development into 
areas of greatest need, and avoid wasting money on unnec-
essary research if the early economic evaluation shows that 
the price of the new technology will need to be too low to 
make a profit. Headroom analysis is one of the key com-
ponents of early economic evaluation. It considers whether 
there is sufficient unmet need for a new technology with 
regards to a specific condition to support a price consist-
ent with an acceptable return on investment. Clearly, early 
economic evaluation has potentially profound advantages 
for technology developers and encouraging companies to 
use this approach has the potential to guide the develop-
ment of new technologies on the basis of need rather than 
trying to find the best fit for them. This analysis considers 
only the Widal test (but not blood culture) because it is 
the better of the two tests currently available in Ghana (in 
terms of accuracy) [16]; therefore, by adopting the Widal 
test as the comparator, the analysis provides a more robust 
examination of the HT-test.
2  Methods
We conducted an early cost-utility analysis to examine the 
potential economic value of the HT-test in the Ghanaian 
setting. In this analysis, the HT-test is the test to be evalu-
ated, and the comparator intervention against which the 
performance of the HT-test is compared is the Widal test. 
The patient population considered is individuals present-
ing with symptoms suggestive of typhoid fever (diagnosis is 
unknown at presentation) at a healthcare facility in Ghana. 
A time horizon of 180 days was chosen because all path-
ways eventually lead to successful treatment and the time 
horizon needs to be at least as long as the longest test–treat 
pathway. In this instance, the longest test–treat pathway was 
34 days. Thus, 180 days was chosen to be an appropriate 
time over which patients will benefit from the effects of test-
ing and treatment for typhoid fever [17]. Also, by taking the 
time horizon to 180 days, it allows other feasible options 
to be added to the model that could have a longer treat-
ment time. The Ghanaian national health service perspec-
tive was adopted for the analysis because the health service 
is the direct payer for healthcare services and the aim of 
this analysis is to support decision making for the Ghanaian 
health service [18]. No discounting of costs and benefits 
was undertaken because the time horizon did not exceed 
12 months [19]. The findings are expressed in terms of cost, 
quality-adjusted life-years (QALYs), and net-monetary ben-
efit (NMB), where NMB is defined for each intervention as
In  Ghana ,  a  cos t -e f fec t iveness  t h resho ld 
of < US$104–US$951/QALY is generally considered to be 
cost effective by policy makers [20]. For this analysis, the 
upper limit of the cost-effectiveness threshold was chosen 
because the lower limit is practically too low and adopting 
the lower threshold value means most interventions could 
never be cost effective.
NMB = QALYs gained ∗ willingness to pay
(WTP) for a QALY−incremental cost.
Early Cost Effectiveness of a Hypothetical Test
2.1  Model Choice
A static model rather than a dynamic model was adopted, 
although it is acknowledged that typhoid fever is an infec-
tious disease. Underpinning this decision is the fact that, 
unlike vaccination where the role of the intervention is to 
reduce the incidence of typhoid transmission (which is best 
captured by a dynamic model) [21], there is no evidence in 
support of early diagnosis and treatment affecting onward 
transmission [22]. In the case of this analysis, the emphasis 
was on evaluation of the direct benefits of testing and treat-
ment to an individual (i.e., survival and quality of life) rather 
than benefits to the population via prevention of onward 
transmission. Furthermore, all the patients in this model are 
assumed to be treated successfully, and because the means of 
typhoid transmission is not direct person-to-person [2], even 
a delay of 3 days until cure is unlikely to contribute substan-
tially to onward transmission. In conclusion, under these 
circumstances, a static model was considered appropriate. 
Decision trees were employed because they are particularly 
suited to acute clinical conditions and typhoid fever is an 
acute condition.
A key determination in test evaluation is the best place-
ment and role (replacement, triage or add-on) of a new 
test on existing pathways. Therefore, as a comparator to 
the Widal test, the HT-test was evaluated in three possible 
roles, resulting in the construction of three decision trees 
(Fig. 1a–c). Each decision tree has two arms (current prac-
tice and the hypothetical testing strategy). The test–treat 
pathway for a suspected typhoid case, for each of the dif-
ferent roles, is as shown in the different decision trees. In 
the replacement role, the HT-test is evaluated to determine 
whether it should be used as the main investigative test with-
out any further testing with the Widal test. In the triage role, 
the HT-test is evaluated to determine whether it should be 
used to test patients first to decide those requiring further 
testing with the Widal test. In the add-on role, the HT-test 
is evaluated to determine whether it should be used to con-
firm diagnosis after testing patients first with the Widal test 
(Fig. 2).
2.2  Test Accuracy
In this analysis, each test is considered to provide either a 
positive or negative test result. This allows the application 
of sensitivity and specificity values to be considered in the 
analysis. The resulting possible test statuses for patients in 
each pathway are as follows: true positive (TP) (has typhoid 
and tests positive for it), true negative (TN) (does not have 
typhoid and tests negative for it), false positive (FP) (does 
not have typhoid but tests positive for it) and false negative 
(FN) (has typhoid but tests negative for it). Given that the 
HT-test is a hypothetical test, there was no information on 
the sensitivity and specificity of the test. Test accuracy val-
ues used for the Widal test are shown in Table 1.
2.3  Model Assumptions
In order to implement a working model, the following 
assumptions were made:
• For a patient presenting with suspected typhoid, if the 
patient does not have typhoid, then it is assumed they 
have malaria because malaria is the most probable dif-
ferential diagnosis [7].
• The results obtained from retesting a patient following a 
treatment failure with the same test are independent of 
those from the first test.
• If the first round of typhoid treatment fails in individu-
als who actually have typhoid, then the second round 
will always be successful. This is because ciprofloxacin 
has been found to be highly active against Salmonellae 
in vivo and repeated treatment is usually associated with 
a 100% cure rate [23].
• For any patient that has malaria, every first treatment is 
successful. This is justified because artemisinin-based 
combination treatments (ACTs) (the first-line drug for 
uncomplicated malaria in Ghana) are rapid and effective 
(effectiveness usually exceeds 95%) [24].
• There is no uncertainty about the length of treatment for 
typhoid and malaria. These are informed by the standard 
treatment guidelines in Ghana.
• All patients experiencing treatment failure return for 
retesting immediately after completion of a treatment 
course.
• Delays on the test–treat pathway (i.e., delay receiving 
test results, delay receiving treatment) are negligible.
• Patients experience the same utility at the differ-
ent phases of treatment as they do when experienc-
ing untreated typhoid symptoms but return to per-
fect health once treatment has been completed. This 
assumption was made because of the paucity of evi-
dence on the impact of treatment on patient quality of 
life.
• Utility when experiencing typhoid symptoms is the 
same as when experiencing malaria symptoms as both 
diseases have similar symptoms during the acute phase 
of illness [25].
2.4  Model Description
Any action taken is dependent on the information available 
to the clinician at that point in time (i.e., test results and 
response to treatment). For example, as shown in the current 
practice arm (Fig. 1), individuals presenting with symptoms 
suggestive of typhoid who test positive and actually have 
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Fig. 1  a Model structure for evaluating hypothetical test in the replacement role. b Model structure for evaluating hypothetical test in the triage 
role. c Model structure for evaluating hypothetical test in the add-on role
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typhoid (TP) are given a first round of typhoid treatment, 
some of whom will be successfully treated and others not. 
TPs experiencing treatment failure are retested and re-test 
TPs are given a second round of typhoid treatment, which 
in the model is assumed to be successful. Retested negatives 
(re-test FN) will be given malaria treatment on the basis that 
Fig. 1  (continued)
Fig. 2  The role and placement of tests in existing care pathways: rapid test for typhoid
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typhoid treatment has been unsuccessful. However, because 
re-test FN patients actually have typhoid, the malaria treat-
ment will be ineffective. They are then given a second round 
of typhoid treatment following the malaria treatment and 
this second round of treatment is assumed to be successful.
2.5  Parameterization
A range of secondary sources was utilized to parameterize 
the model. These secondary sources were identified through 
extensive searching of published literature, websites of gov-
ernment departments in Ghana (Bank of Ghana), and the 
National Health Insurance Scheme tariff of Ghana (2016). 
Table 1 shows the parameters used in the economic analysis 
along with the data source. Given that this is an early eco-
nomic evaluation, the parameters describing the characteris-
tics of the HT-test were unknown, and thus these parameters 
were subject to extensive sensitivity analysis to draw conclu-
sions about the characteristics of this test necessary for it to 
be cost effective.
Table 1  Model parameters used in the economic analysis along with the data source
CI confidence interval, OPD outpatient department, QALY quality-adjusted life-year, SD standard deviation, VOI value of information
Parameter Estimate Data source
Sensitivity and specificity values for the Widal test
 Sensitivity of Widal test (CI) 0.69 (0.61–0.75) [16]
 Specificity of Widal test (CI) 0.83 (0.77–0.88) [16]
Probability estimates utilized in the economic analysis
 Probability of successful first typhoid treatment 0.95 [28]
 Prevalence of typhoid in the patient population presenting 0.48 [29]
Parameter estimates used to inform QALY values
 Utility when experiencing typhoid symptoms (CI) 0.867 (0.81–0.912) [17]
 Perfect health utility 1 By definition: [19]
 Time horizon of model (days) 180 [17]
 Number of days per typhoid treatment 14 [10]
 Mean recovery time for successful typhoid treatment (SD) 3.68 (0.92) [28]
 Number of days per malaria treatment 3 [10]
 Mean recovery time for successful malaria treatment (SD) 1.83 (0.95) [30]
Parameter Unit cost (US$) Data source
Cost parameters
 Widal test 1.28 [31]
 Blood culture 2.29 [31]
 Ciprofloxacin 1.35 [31]
 Artemether/lumefantrine 0.79 [31]
 OPD tariff per visit 3.62 [31]
Model parameters with uncertainty Parameters of beta distribution Data source
a b
Mean recovery time for successful typhoid treatment (this is a fraction of the 
length of treatment for typhoid)
9.95 28.32 Estimated
Mean recovery time for successful malaria treatment (this is a fraction of the 
length of treatment for malaria)
0.85 0.55 Estimated
Prevalence of typhoid in the patient population presenting 22 24 Estimated
Probability of successful first typhoid treatment 38 2 Estimated
Utility when experiencing typhoid symptoms 145.48 22.32 Estimated
Parameters used in the VOI analysis Estimate Data source
Number of people affected by decision annually (incidence) 60,000 [8]
Decision relevance time horizon 5 years Expert opinion
Discounting rate 3.5% [19]
Total discounted incidence over 5 years 280,385 Estimated
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2.5.1  Measurement of Effects
The primary outcome measure was the QALY. Total QALYs 
were estimated for each branch based on the parameters 
described in Table 1.
For every round of unsuccessful treatment, the total num-
ber of days per treatment is included in the estimation, and 
for every successful treatment, the mean recovery time for 
successful treatment is also included. For example, total 
QALYs for a branch where a patient receives two rounds of 
typhoid treatment (i.e., one unsuccessful and one success-
ful) was calculated as [(U1T1) + (U1T2) + (U2T3)]/365 days.
Where U1 is the utility when experiencing typhoid symp-
toms, T1 is the number of days per typhoid treatment, T2 is 
the mean recovery time for successful typhoid treatment, U2 
is the perfect health utility, and T3 is the number of days in 
perfect health after two typhoid treatments.
The time horizon (TH) has been incorporated into the 
above calculation as follows:
2.5.2  Costs
Total cost for each branch was estimated based on the per-
spective of the Ghanaian national health service for the 2018 
cost year. All costs were converted to US dollars (US$) by 
using the exchange rate (Gh₵1 = US$0.225) adopted from 
the website of the Bank of Ghana at the time of analysis (29 
March 2018, Bank of Ghana, 2018). Table 1 shows the costs 
used in the economic analysis. Ciprofloxacin and artemether/
lumefantrine are the first-line drugs of choice for typhoid 
and malaria treatment, respectively, in Ghana.
The total cost for a branch where a patient has visited 
a health facility once, received the Widal test, and then 
typhoid treatment is estimated as follows:
The OPD (outpatient department) tariff is an amount 
reimbursable to the service provider per visit to cover other 
costs like staff time and consultation. On any pathway where 
initial treatment is unsuccessful, there will be more than one 
visit and, in such instances, the OPD tariff is multiplied by 
the number of visits and added to the other costs incurred to 
estimate the total cost for that branch.
2.6  Dealing with Uncertainty
There was no information on test accuracy or cost of the new 
test. Thus, each of these parameters was a separate focus 
of sensitivity analysis. Headroom analysis (i.e., maximum 
cost at which the new technology is still cost effective at a 
T3 = TH−
(
T1 + T2
)
.
cost of Widal test + cost of ciprofloxacin
+ OPD tariff per visit = $6.25.
given WTP threshold) using NMB was conducted. The price 
at which the NMB of using the HT-test equals the NMB 
of using the Widal test gives information on the headroom 
price of the HT-test compared with the Widal test. Further-
more, sensitivity and specificity pairs for the HT-test were 
varied and the maximum price for each pair determined. 
This analysis gave information on how good the test needs 
to be (in terms of accuracy), and at what price, for it to be 
cost effective. By varying accuracy pairs for the HT-test, the 
incremental effectiveness for each accuracy pair could be 
determined and information on which accuracy pairs pro-
vide the most benefit to patients within cost-effectiveness 
constraints could be identified.
Probabilistic sensitivity analysis (PSA) was also con-
ducted. A probability distribution was defined for each 
uncertain parameter (Table  1). A beta distribution was 
assigned to all uncertain parameters except the test accu-
racy parameters of the Widal test. Table 1 shows the beta 
distributions assigned to each of the uncertain model param-
eters. Sensitivity and specificity are correlated and therefore 
required a different method that accounts for the correlation 
between these parameters [26]. Data from a meta-analysis 
of typhoid diagnostic accuracy studies [16] were utilized to 
obtain the hierarchical summary receiver operating charac-
teristic (HSROC) curves for the Widal test. Using the Stata 
function, metandi, to obtain the HSROC curve and the fol-
lowing equation that links sensitivity to any given specific-
ity, it was possible to take a value of specificity and calculate 
a corresponding sensitivity along the HSROC curve.
where lambda (훬) is the mean of the accuracy parameter and 
beta (훽) is the shape parameter.
These distributions were then sampled for the PSA. The 
model was run 1000 times, each time randomly selecting a 
value for each parameter from their respective distributions. 
Mean costs and mean QALYs were calculated by averaging 
across all 1000 simulations. Cost-effectiveness acceptability 
curves (CEACs) were drawn to gain a greater understanding 
of realistic price and test accuracy parameters.
2.7  Value of Information (VOI) Analysis
Value of information (VOI) analysis was conducted to pro-
vide insights into the value of conducting further research 
from the perspective of the healthcare provider in Ghana. 
In the absence of information on test accuracy parameters 
of the HT-test and specific guidance on VOI analysis at this 
early stage of analysis, the assumption was made that the 
same distributions for accuracy characteristics could be 
used for the HT-test as the Widal test, sampling indepen-
dently for the two sets. The VOI analysis was repeated for 
different prices in each role as informed by the results of the 
logit(sensitivity) = 훬e − 훽∕2 − e − 훽logit(specificity),
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headroom analysis. Table 1 shows the parameters used in 
the VOI analysis.
In VOI analysis, insight into the parameters that cause the 
most decision uncertainty and the potential value of reduc-
ing the uncertainty by collecting more data were examined 
using expected value of partial perfect information (EVPPI). 
In this study, EVPPI was estimated using SAVI (Sheffield 
Accelerated Value of Information) [27].
3  Results
3.1  Headroom Analysis Using Net‑Monetary Benefit 
(NMB)
As shown in Fig. 3, taking all parameters at baseline, at a 
WTP of US$951 per QALY, the HT-test can be priced up 
to US$3.85 and still be cost effective against the Widal test 
in the replacement role. The maximum prices at which the 
HT-test can be priced and still be cost effective against the 
Widal test in the triage and add-on roles are US$1.94 and 
US$1.47, respectively (see Appendix in the electronic sup-
plementary material [ESM]).
3.2  Incremental Effectiveness (QALYs) Varying 
Sensitivity and Specificity Pairs
Tables 2 and 3 show the incremental effectiveness and the 
maximum price at which the HT-test is still cost effective 
at each sensitivity and specificity pair for the HT-test vs. 
Widal test in the replacement role. The tables for the triage 
and add-on roles are presented in the Appendix (see ESM). 
As shown in the set of tables (Tables 2, 3), the HT-test 
can be priced up to US$3.85 and still be cost effective 
against the Widal test in the replacement role when the 
HT-test has both sensitivity and specificity of 100%. In 
this case, the incremental effectiveness is 0.0010. When 
the HT-test has both sensitivity and specificity of 70%, it 
can be priced up to US$0.95 and still be cost effective; 
however, here the incremental effectiveness is − 0.0002. 
This means that as the accuracy of the HT-test decreases, 
the maximum price of the HT-test for it to be cost effective 
against the Widal test in the replacement role reduces with 
a decrease in incremental effectiveness. The same observa-
tion is made for the triage and add-on roles.
Fig. 3  Headroom of the HT-test 
vs. Widal test at a WTP of 
$951/QALY (replacement role)
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3.3  Cost‑Effectiveness Acceptability Curves 
(Replacement Role)
Using a reasonable price range for the HT-test of 
US$1.00–US$4.00, which was informed by findings shown 
in Tables 2 and 3, the CEACs for the PSA of the HT-test 
vs. the Widal test in the replacement role are presented 
below. The set of figures for the triage and add-on roles are 
presented in the Appendix (see ESM). In the CEACs, the 
price is fixed whereas sensitivity and specificity are varied 
using the following pairs of values (1:1; 0.6:1; 1:0.6; 0.9:0.9; 
0.7:0.9; 0.9:0.7; 0.8:0.8; 0.7:0.7).
The results show that specificity is a major driver of 
the probability of the HT-test being cost effective at the 
threshold value adopted. For any price above the estimated 
headroom, the HT-test was always < 50% likely to be cost 
effective at the WTP threshold, even for the most optimistic 
scenario for the HT-test (i.e., both sensitivity and specificity 
of 100%). For example, the headroom price for the HT-test 
in the replacement role as shown in Table 3 is US$3.85. 
From Fig. 4a, at a price of US$4 (which is above the head-
room), the HT-test is < 50% likely to be cost effective, even 
when both sensitivity and specificity are 100%. The results 
further show that when the price is low (below the price of 
the Widal test) (in this case US$1), then all the pairs with 
positive expected incremental effectiveness have a 100% 
probability of being cost effective (Fig. 4b).
Table 2  Incremental 
effectiveness (QALYs) at each 
sensitivity and specificity pair 
for the HT-test vs Widal test 
(replacement role)
100 0.0010 0.0007 0.0004 0 -0.0005 -0.001 -0.0016 -0.0022 -0.0029 -0.0036
90 0.0010 0.0007 0.0003 -0.0001 -0.0005 -0.0011 -0.0016 -0.0022 -0.0029
80 0.0009 0.0006 0.0003 -0.0001 -0.0006 -0.0011 -0.0017 -0.0023
Se
ns
iti
vi
ty
70 0.0009 0.0006 0.0002 -0.0002 -0.0007 -0.0012 -0.0017
60 0.0008 0.0005 0.0002 -0.0003 -0.0007 -0.0012
50 0.0007 0.0004 0.0001 -0.0003 -0.0008
40 0.0007 0.0004 0 -0.0004
30 0.0006 0.0003 0
20 0.0006 0.0003
10 0.0005
0
100 90 80 70 60 50 40 30 20 10 0
Specificity
Table 3  Maximum price (US$) at which the HT-test is still cost effective at each sensitivity and specificity pair for the HT-test vs Widal test 
(replacement role)
100 3.85 3.13 2.40 1.64 0.86 0.06 NV NV NV NV
90 3.59 2.89 2.16 1.41 0.64 NV NV NV NV
80 3.33 2.64 1.92 1.18 0.42 NV NV NV
Se
ns
iti
vi
ty
70 3.07 2.39 1.69 0.95 0.2 NV NV
60 2.82 2.15 1.45 0.73 NV NV
50 2.56 1.91 1.22 0.5 NV
40 2.31 1.67 0.99 0.28
30 2.06 1.43 0.76
20 1.81 1.19
10 1.56
0
100 90 80 70 60 50 40 30 20 10 0
Specificity
NV represents negative values for price and implies that the HT-test cannot be cost effective at these sensitivity and specificity pairs and the end 
user of the test would have to be paid for using the test. Shaded black cells represent cases where either the test is completely useless, or it would 
be better to take the reverse of the test results
Values in bold format represent price at sensitivity and specificity pairs at which the HT-test is still cost effective and has a positive incremental 
effect, and would normally be of interest to a decision maker
Values in italic format represent price at sensitivity and specificity pairs at which the HT-test is still cost effective but is slightly less effective 
than the Widal test
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3.4  VOI Results
Using sensitivity and specificity for the HT-test sampled 
from the same distribution for the Widal tests and a price of 
US$1 informed by the CEACs, the results of the VOI analy-
sis for the replacement role are presented below. The results 
for the triage and add-on roles are presented in the Appen-
dix (see ESM). As shown in Fig. 5, at the WTP threshold 
adopted, the overall expected value of perfect information 
(EVPI) for the specified decision relevance time horizon of 
5 years is US$3287.
Table 4 shows the EVPPI for each of the uncertain model 
parameters at the adopted WTP threshold. As shown in 
Table 4, specificity of the HT-test and Widal test are the 
two parameters causing most of the decision uncertainty. 
The standard error values also indicate that sufficient repli-
cations were undertaken.
Table 5 shows the percentage likelihood of the HT-test 
being cost effective compared with the Widal test at a given 
price and accuracy pair for the HT-test at the adopted WTP 
threshold. For example, at a price of US$2 and test accuracy 
parameters of sensitivity 60% and specificity 100%, the HT-
test is 63% likely to be cost effective in a replacement role 
compared with the Widal test. The results also show that, 
as the price of the HT-test drops, more and more pairs of 
sensitivity and specificity values become cost effective.
Table 6 shows that for the assumptions made about the 
HT-test, the EVPI per person is US$0.00 when the HT-test is 
US$2.00; thus, the overall EVPI for 5 years is also US$0.00. 
This indicates that research into other parameters to resolve 
uncertainty is not worth doing based on the assumptions 
made about the HT-test. The EVPPI results also show that 
at this price (US$2.00) there is no uncertainty associated 
with the individual model parameters as an inevitable con-
sequence of the overall EVPI being zero.
The results further show that, regardless of the scenario, 
mean recovery time for successful typhoid treatment, mean 
recovery time for successful malaria treatment, probability 
of successful first typhoid treatment and the sensitivity of 
the HT-test do not contribute to the decision uncertainty. 
Overall, the prevalence of typhoid in the patient population, 
the specificity of the Widal test, and the specificity of the 
HT-test can be seen to be the parameters contributing to 
most of the decision uncertainty in the analysis.
Fig. 4  a CEAC (with variations 
in the sensitivity and specificity 
of the HT-test at a fixed price of 
$4.00) at different WTP values 
(replacement role: the HT-test 
vs. Widal test). b CEAC (with 
variations in the sensitivity and 
specificity of the HT-test at a 
fixed price of $1.00) at different 
WTP values (replacement role: 
the HT-test vs. Widal test)
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4  Discussion
Using a model-based economic evaluation with the outcome 
measure of the QALY, this study sought to identify the key 
characteristics of a hypothetical test for typhoid diagnosis for 
it to be cost effective in the Ghanaian context compared with 
the Widal test. A particular focus of this evaluation was the 
position of the HT-test on the testing pathway.
The headroom analysis (where the assumption is made 
that the HT-test is 100% accurate) shows that the HT-test can 
be priced up to US$3.85 and still be cost effective against 
the Widal test in the replacement role. The maximum prices 
at which the HT-test can be priced and still be cost effec-
tive against the Widal test in the triage and add-on roles 
are US$1.94 and US$1.47, respectively. Thus, if it is not 
possible to develop the HT-test so that it can be sold below 
these prices and make a profit, then resources should not 
be committed to its further development. Furthermore, it 
can be concluded that a test developer will gain most from 
the new test replacing current practice. It is worth stating 
that although a higher price allows for a greater chance of 
a return on investment, it also increases the possibility of 
rejection on budget impact grounds.
Acknowledging that the headroom price (when the HT-
test is 100% accurate) is probably going to be unrealistic, 
the focus turns to how accurate the HT-test needs to be to 
be cost effective. Additional information on the value of the 
HT-test compared with the Widal test in each of the roles 
was considered based on effectiveness (QALYs) and head-
room prices. For example, it is shown that the HT-test can be 
priced up to US$3.85 and still be cost effective against the 
Widal test in the replacement role when the HT-test has sen-
sitivity and specificity of 100%. In this case, the incremental 
effectiveness is 0.0010. When the HT-test has a sensitivity 
and specificity of 70%, the maximum price at which it can 
still be cost effective is US$0.95 but with an incremental 
effectiveness of − 0.0002. This indicates that as the accuracy 
of the HT-test decreases, the maximum price at which the 
HT-test can be priced and still be cost effective against the 
Widal test in the replacement role must also decrease. This 
implies that greater potential returns on investment are pos-
sible with a better test. Although care must be taken when 
recommending a test with characteristics that lead to a nega-
tive effectiveness, as further factors beyond cost effective-
ness may need to be considered for the test to be acceptable 
to decision makers (e.g., small decrease in effectiveness 
coupled with large cost savings). The maximum price at 
which the test can be sold after development when both 
sensitivity and specificity are 100% is far greater and more 
attractive to investors compared with when both parameters 
are 70% (US$3.85 compared with US$0.95) and the incre-
mental effectiveness is also more attractive from the patient 
perspective (i.e., 0.0010 compared with − 0.0002). Similar 
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Fig. 5  VOI analysis of the HT-test vs. Widal test in the replacement 
role at a price of $1.00
Table 4  Single-parameter 
EVPPI
The standard error shows whether there have been enough replications in the model
EVPPI expected value of partial perfect information
Model parameters with uncertainty Per person 
EVPPI (US$)
Standard 
error
EVPPI for Ghana 
over 5 years (US$)
Mean recovery time for successful typhoid treatment 0 0 0.00
Mean recovery time for successful malaria treatment 0 0 0.00
Prevalence of typhoid in the patient population presenting 0 0 0.00
Probability of first successful typhoid treatment 0 0 0.00
Utility when experiencing typhoid symptoms 0 0 0.00
Specificity of Widal test 0.000222 0 62
Sensitivity of Widal test 0 0 0.00
Specificity of the HT-test 0.001010 0 283
Sensitivity of the HT-test 0 0 0.00
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Table 5  Summary of headroom and percentage likelihood of cost-effectiveness results for the HT-test vs Widal test
Role Headroom price (US$) Incremental effectiveness (QALYs) (positive 
range)
Price range (US$) (across range of 
positive incremental effectiveness)
Replacement 3.85 0–0.0010 (specificity at least 70%) 1.64–3.85 (specificity at least 70%)
Triage 1.94 0–0.0003 (specificity at least 90%) 0.34–1.94 (specificity at least 90%)
Add-on 1.47 0–0.0002 (specificity at least 90%) 0.76–1.47 (specificity at least 90%)
Role Price (US$) Percentage likelihood of being cost effective at threshold for the following accuracy pairs (sensitivity, 
specificity)
(1, 1) (0.6, 1) (1, 0.6) (0.9, 0.9) (0.7, 0.9) (0.9, 0.7) (0.8, 0.8) (0.7, 0.7)
Replacement 4.00 0
3.00 72 0 0 0 0 0 0 0
2.00 100 63 0 89 7 0 0 0
1.00 100 100 2 100 100 19 95 0
Triage 2.00 3
1.00 100 63 0 52 7 0 0 0
0.50 100 100 1 99 91 7 33 0
Add-on 2 2
1.00 76 11 0 5 0 0 0 0
0.50 100 91 0 34 10 0 1 0
Table 6  Summary of VOI analysis for the HT-test vs. the Widal test
EVPI expected value of perfect information, EVPPI expected value of partial perfect information, VOI value of information
Role Price (US$) EVPI per person Overall EVPI for the decision-
relevant time horizon (5 years)
Replacement 2.00 0.00 0.00
1.00 0.011723 3287
Triage 1.00 0.001029 289
0.50 0.066283 18585
Add-on 1.00 0.000082 23
0.50 0.001449 406
Role Price 
(US$)
EVPPI per person (overall EVPPI for 5 years)
Mean 
recovery 
time for 
successful 
typhoid 
treatment
Mean 
recovery 
time for 
successful 
malaria 
treatment
Prevalence 
of typhoid 
in the 
patient 
population 
presenting
Probability 
of first 
successful 
typhoid 
treatment
Utility 
when 
experi-
encing 
typhoid 
symptoms
Specificity 
of Widal 
test
Sensitivity 
of Widal 
test
Specificity 
of HT-test
Sensitivity 
of HT-test
Replace-
ment
2.00
1.00 0.000222 
(62)
0.001010 
(283)
Triage 1.00 0.000109 
(30.68)
0.50 0.05 
(14,019)
0.000024 
(7)
0.000040 
(11)
0.000265 
(74)
0.010029 
(2812)
Add-on 1.00
0.50 0.000307 
(86)
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conclusions can be drawn for the other roles of the HT-test 
vs. Widal test.
The PSA results indicate that as the price of the HT-test 
drops, more and more pairs of sensitivity and specificity 
become cost effective (i.e., the PSA supports the main find-
ings). The PSA results help to provide a greater understand-
ing of a realistic price and test accuracy parameters for the 
HT-test to be cost effective. For example, in the replacement 
role the headroom price is US$3.85; however, at this price 
the PSA reveals that the HT-test is likely to be cost effec-
tive only when both sensitivity and specificity are 100%. 
Acknowledging the fact that no test is likely to be 100% 
accurate, it is not realistic for investors to invest in the devel-
opment of a new test at this price and with these accuracy 
pairs.
The PSA results also show that specificity (at least 70%) 
is a major driver of the probability of the HT-test being cost 
effective at the adopted WTP threshold. This observation 
is explained by the prevalence of typhoid in the patient 
population and what happens to FPs and FNs following the 
test–treat pathway for a suspected typhoid case as shown in 
the different decision trees. From the models, FP is worse for 
patients than FN because of the extra testing and treatments 
patients undergo before they are eventually cured. Thus, a 
high specificity is required in order to avoid the unnecessary 
testing and treatment associated with these pathways.
It is shown in the VOI analysis (in the replacement role) 
that for the specified decision relevance time horizon of 
5 years, and for an annual incidence of 60,000, the overall 
expected value of removing decision uncertainty when the 
HT-test is US$1.00 would be US$3287. This implies that 
research or data collection exercises costing more than this 
amount would not be a cost-effective use of resources to 
resolve this decision uncertainty. This is because the cost of 
making a wrong decision by the decision maker, as meas-
ured by the cost savings of enabling the decision maker’s 
ability to switch and select other strategies when evidence 
obtained reduces decision uncertainty, is expected to be no 
higher than US$3287. From this value, it can be concluded 
that there might be no value in resolving this uncertainty 
as any research studies on further data collection are likely 
to cost more than this amount. The VOI analysis further 
shows that different parameters (prevalence of typhoid in the 
patient population, utility when experiencing typhoid symp-
toms, sensitivity and specificity of the Widal test, specificity 
of the HT-test) contribute to the decision uncertainty. These 
results will be of interest to a technology developer as it 
shows where future research should be focussed. The calcu-
lations presented here assume immediate and 100% uptake. 
This is because a recent qualitative study by this study team 
shows that, in the Ghanaian setting, patients are most likely 
to take a test requested by their clinician [32] and, because 
the new technology would be administered in the same way 
as the current technology, uptake is likely to be the same for 
both tests, and therefore its exclusion should not impact on 
conclusions drawn from the model.
This work demonstrates the importance of early eco-
nomic evaluation as a tool in priority setting by providing 
insight into whether to fund the further development of a 
new product, thereby helping to allocate limited budget more 
efficiently. Moreover, this study has demonstrated how mod-
elling can be used to consider different test–treat pathways 
and draw conclusions about the optimum placement of a 
new technology on a care pathway. Specific to the context 
of this study, it has shown that in the developing world con-
text, the cost-effectiveness threshold is very low, and thus, 
does not provide much headroom in which to develop new 
technologies. The findings of this study have wider implica-
tions for the early economic evaluation of diagnostic tests by 
contributing to a limited evidence base and identifying areas 
requiring further research.
Early economic evaluations are typically characterized by 
a lack of data to populate models. In the absence of such evi-
dence, expert judgement may be relied upon for model param-
eterization and assisting in model structure conceptualization. 
However, unless the early economic model is for a specific 
technology in development, where experts can provide insights 
into the characteristics of the technology (e.g., cost and effec-
tiveness), then expert elicitation to inform parameters related 
to the new technology may not be necessary.
4.1  Strengths and Limitations of the Study
A strength of this analysis is that extensive sensitivity analysis 
has been conducted to identify the impact of key parameters 
on the conclusions drawn from the models. It also highlights 
the usefulness of early cost-effectiveness modelling embedded 
within the test development pathway.
A limitation of this analysis is that there was no specific 
guidance on the best approach to VOI analysis at such an 
early stage of development to be adopted and how to manage 
parameters when they are completely unknown and hypotheti-
cal. Thus, the approach to VOI analysis adopted in this study 
may not be the most appropriate, highlighting the need for 
further work in this field. Another limitation of this study is 
the completely hypothetical nature of the test. Having some 
form of data on the new test would have been far better than 
not having any data.
5  Conclusion
This evaluation has presented a complete analysis of the poten-
tial benefits of the HT-test compared with the Widal testing 
pathway in each of three different roles. The analysis shows 
that at certain prices and accuracy pairs for the HT-test, the 
HT-test has potential to be more effective compared with the 
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Widal test in terms of QALYs gained and cost effectiveness. 
A high specificity (at least 70%) is a key test characteristic 
requirement for the HT-test to be able to improve current prac-
tice, and the HT-test is likely to improve current practice when 
used to replace the currently used test. The overall value of 
conducting research to reduce uncertainty (over 5 years) is 
US$18,585.
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